NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered Tirzepatide from Mai Peptide? Mail in a sample (US only) and let us test it.

Test my supply
+3 more ↓
63%
Finnrick rating
#271 of 281 Tirzepatide vendors
17 of 29 classifiable tests passed
natural 59% · customers 4.6★ (18)
methodology · Purity focus
Finnrick analysis · Tirzepatide

Mai Peptide tirzepatide is weighed down by repeated purity misses and two recent identity failures, not just older noise. Key details are July/August identity fails, September's 91.1% purity, and a later pass that only partly steadies it.

methodology →
vendor intelligence report
Vendor Intelligence Report: Mai Peptide

Corporate and domain records point past the storefront to a Xi'an/Shaanxi sales trail, HK-numbered contacts and unresolved UBO. The report maps Carrd COAs, crypto/off-platform payment rails, lookalike domains and parasite-review promotion.

37 pages9 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Retatrutide
$0.77
84%
40
2
GHK-Cu
$0.06
83%
16
3
Ipamorelin
$0.90
76%
8
4
Tirzepatideselected
$0.30
63%
29
5
Tesamorelin
$2.20
59%
7
6
Cagrilintide
$2.40
56%
5
8
BPC-157
$0.70
48%
7
9
CJC-1295
$1.50
37%
3
10
TB-500
$1.20
35%
4
11
NAD+
$0.02
28%
3
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%25 Nov 2025: 74%17 Dec 2025: 75%1 Jan 2026: 77%9 Jan 2026: 74%15 Jan 2026: 75%19 Jan 2026: 76%29 Jan 2026: 78%2 Feb 2026: 73%2 Feb 2026: 69%2 Feb 2026: 65%2 Feb 2026: 62%2 Feb 2026: 58%4 Feb 2026: 60%4 Feb 2026: 61%18 Feb 2026: 58%4 Mar 2026: 55%6 Mar 2026: 57%6 Mar 2026: 58%6 Mar 2026: 60%6 Mar 2026: 61%8 Jun 2026: 64%1 Jul 2026: 65%30 Jul 2026: 63%21 Aug 2026: 60%4 Sep 2026: 62%7 Sep 2026: 63%18 Sep 2026: 64%25 Sep 2026: 62%6 Oct 2026: 63%15 Nov 2026: current 63%74%64%63%Nov 25Nov 26
Showing Tirzepatide tests only
Peptide testing

Ordered Tirzepatide from Mai Peptide? Mail in a sample (US only) and let us test it.

Test my supply
Mai Peptide Tirzepatide test history
COA-backed lab tests
1-10 of 29

About Mai Peptide test results from Finnrick

Mai Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 11 peptides and 125 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Mai Peptide peptides in this dataset are Semaglutide (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 125 recent tests.

Corrections
No corrections.
Peptide testing

Ordered Tirzepatide from Mai Peptide? Mail in a sample (US only) and let us test it.

Test my supply